GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (ASX:SPL) » Definitions » Other Cash Payments from Operating Activities

Starpharma Holdings (ASX:SPL) Other Cash Payments from Operating Activities : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Starpharma Holdings Other Cash Payments from Operating Activities?

Starpharma Holdings's Other Cash Payments from Operating Activities for the six months ended in Dec. 2023 was A$0.00 Mil.

Starpharma Holdings's Other Cash Payments from Operating Activities for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.


Starpharma Holdings Other Cash Payments from Operating Activities Historical Data

The historical data trend for Starpharma Holdings's Other Cash Payments from Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings Other Cash Payments from Operating Activities Chart

Starpharma Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Cash Payments from Operating Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Starpharma Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Cash Payments from Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Starpharma Holdings Other Cash Payments from Operating Activities Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Other Cash Payments from Operating Activities represents cash flow paid from other operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Payments" section for non-financial companies:
Payments to Suppliers for Goods and Services
Payments on Behalf of Employees
Other Cash Payments from Operating Activities

Other Cash Payments from Operating Activities for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Starpharma Holdings Other Cash Payments from Operating Activities Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's Other Cash Payments from Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


Starpharma Holdings (ASX:SPL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (ASX:SPL) » Definitions » Other Cash Payments from Operating Activities
Traded in Other Exchanges
Address
4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.

Starpharma Holdings (ASX:SPL) Headlines

No Headlines